Loomis, Sayles & Company
SANA icon

Loomis, Sayles & Company’s Sana Biotechnology SANA Stock Holding History

Loomis, Sayles & Company’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-502
Closed -$11K – 883
2021
Q3 		$11K Buy
+502
New +$10.5K ﹤0.01% 790

Other funds holding SANA

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Public Sector Pension Investment Board (PSP Investments)
Public Sector Pension Investment Board (PSP Investments) Montreal, Quebec, Canada $38.7B AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Loomis, Sayles & Company's SANA Position: Q4 2021 in Review

Loomis, Sayles & Company sold out of Sana Biotechnology (SANA) in Q4 2021, closing a stake of 502 shares — an estimated $11K sold.

Loomis, Sayles & Company first reported a position in SANA in Q3 2021 and held it in 1 quarter. The position peaked at $11K in Q3 2021. 105 funds tracked by Wall St. Rank hold SANA as of Q4 2021.

  • Loomis, Sayles & Company reported no remaining Sana Biotechnology position as of Q4 2021 after selling out during the quarter.
  • Loomis, Sayles & Company sold 502 Sana Biotechnology shares in Q4 2021, an estimated $11K.
  • Loomis, Sayles & Company first reported a position in Sana Biotechnology in Q3 2021 and held it in 1 quarter.
  • Loomis, Sayles & Company's Sana Biotechnology position peaked at $11K in Q3 2021.
  • 105 funds tracked by Wall St. Rank held Sana Biotechnology as of Q4 2021.

Based on Loomis, Sayles & Company's 13F filing for Q4 2021, filed 14 Feb 2022.